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Abstract 
The recently discovered nonprimate hepacivirus (NPHV) naturally infects horses and is the closest known homolog of 
hepatitis C virus to date. Within a follow-up study acute field infections were monitored in four young Thoroughbred 
horses until the ages of 12–13 months. Serum samples were analyzed for the presence of NPHV RNA and anti-NPHV 
NS3 antibodies and liver specific parameters were evaluated. The four young horses were not able to clear infec-
tion, but remained chronically infected for the entire monitored time period despite the presence of NPHV specific 
antibodies.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Nonprimate hepacivirus (NPHV) was described to infect 
horses in several countries worldwide and represents a 
new member within the family Flaviviridae, genus Hepa-
civirus [1, 2]. Among all hepaciviruses, NPHV is the clos-
est known homolog of hepatitis C virus (HCV) to date. 
HCV is a major human pathogen with approximately 
146 million people infected worldwide [3]. In 75–85% of 
acutely infected patients progression to chronic disease 
occurs, which can lead to hepatic fibrosis, cirrhosis and 
carcinoma [4]. In recent years, similar as well as distinct 
features between HCV and NPHV have been described. 
NPHV is highly prevalent in horses with 30–40% sero-
positivity and 3% viremia [1, 5–10]. However, disease 
association remains uncertain although several studies 
reported subclinical hepatitis in infected horses. A mild 
elevation of serum liver enzymes was observed at sero-
conversion in some affected horses, although in most 
horses serum liver enzymes remained within the refer-
ence range [7, 11, 12]. Single reports exist about NPHV 
infected horses suffering from severe hepatitis. Yet, a 
causative relationship still needs to be confirmed [12, 13]. 
Comparable to HCV infection, hepatotropism has been 
confirmed for NPHV [11, 14]. Nevertheless, the routes 
of NPHV transmission remain mostly unclear. Similar to 
HCV a parenteral infection route via direct blood–blood 
contact has been described in horses by experimental 
inoculation with infectious plasma containing NPHV 
[12]. In a recent study, we investigated twenty mare-foal 
pairs at parturition until 6 months postpartum and could 
show the occurrence of vertical transmission of NPHV at 
parturition [15]. Moreover, we observed transmission of 
NPHV isolates within the respective pasture herds indi-
cating the possibility of a direct transmission between 
horses. Interestingly, we could show that several foals 
became viremic within the first 6  months of life [15]. 
To shed some light on the course of naturally acquired 
NPHV infection of the young horses, we aimed to per-
form a follow-up study by monitoring four foals (foal # 9, 
# 10, # 17 and # 19) until the age of 12–13 months.
Materials, methods and results
Blood samples were taken from these four foals at indi-
cated time points (Figure  1; Table  1). All samples were 
obtained with full owner consent as part of routine 
health management. Additionally, a general examina-
tion of the foals was conducted at all investigated time 
points. Next, sera was analyzed for the presence of NPHV 
RNA and anti-NPHV NS3 antibodies by a SYBR Green 
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based quantitative real-time PCR (qRT-PCR) and lucif-
erase immunoprecipitation assay (LIPS), respectively, as 
described earlier [1, 11, 15]. As shown in Figure 1, NPHV 
RNA was detected in the serum of all foals 6 months after 
birth. From the initial virus detection onwards the four 
acutely infected young horses remained viremic with high 
viral loads during the entire monitored 7 months and none 
of them eliminated the virus until the last sampling at the 
age of 12–13 months (Figure 1A–D). For the foals # 9, # 
10 and # 19 anti-NPHV NS3 antibodies were detected at 
the time point of birth, decreased until 6 months postpar-
tum below or close to the cut-off of the assay and NPHV 
specific antibodies appeared again after NPHV RNA was 
detected in the serum (Figure 1A, B and D). Of note, foal 
# 17 was the only foal not receiving maternal anti-NPHV 
NS3 antibodies after foaling and became newly infected 
at a similar age as the remaining foals and production of 
anti-NPHV NS3 antibodies was observed from the age of 
10 months onwards (Figure 1C). In Table 1 details on the 
NPHV RNA and anti-NPHV NS3 antibody status of the 
follow-up samples of the four horses are given (Table 1). 
To investigate the clinical relevance of NPHV infection 
for liver disease, the horses were clinically examined and 
blood was analyzed for the liver specific enzymes gluta-
mate dehydrogenase (GLDH), γ-glutamyl-transferase 
(GGT) and aspartate aminotransferase (AST) in the labo-
ratory of the small animal clinic at the University of Vet-
erinary Medicine Hannover, Foundation. Results for each 
sampling time point are shown in Figure 1, lower panels. 
A mild elevation of liver enzymes was observed at the age 
of 12–13 months for foals # 9, # 17, and # 19. However, 
values of all other time points remained within the refer-
ence range and no clinical signs indicating liver disease 
were found at any sampling time point.
In conclusion, four acutely infected foals developed 
chronic infection and remained viremic with high viral 
loads during the entire monitored 7 months. Despite the 
presence of anti-NPHV NS3 antibodies, the four young 
horses were not able to clear the infection within the 
monitored time period.
Discussion
This study provides the first description of the clinical 
course of naturally acquired NPHV infection in young 
horses. This follow-up study was conducted in the context 
of a previous study investigating the occurrence of vertical 
transmission of NPHV in a horse cohort, where we moni-
tored twenty Thoroughbred broodmares and their foals 
from parturition until 6  months after foaling [15]. Here, 
we monitored four of these foals for another 7  months. 
These foals became NPHV RNA positive at the age of 
6 months and stayed viremic for another 7 months with 
the concurrent detection of anti-NPHV NS3 antibodies. 
The activity of liver specific enzymes increased in three 
foals at the ages of 12–13 months. The mild elevation of 
enzyme activity could indicate a subclinical hepatitis due 
to the persistent NPHV infection. For reliable diagnosis 
liver biopsies would be required, since the elevation of 
liver enzymes might have had an unrelated reason.
(See figure on previous page.) 
Figure 1 Course of infection in the four foals # 9, # 10, # 17 and # 19 from parturition until the ages of approximately 13 months. 
Serum samples from the first three sampling time points (at parturition and at the ages of 3 and 6 months are derived from a previous study 
(marked with a grey background) [15]. Until the ages of 12–13 months these foals were further monitored within this follow-up study and serum 
was taken at three additional time points. All serum samples were analyzed for the presence of anti-NPHV NS3 antibodies (ab) (grey bullet) and 
NPHV RNA (black square) by LIPS and qRT-PCR, respectively. The cut-off limit for the LIPS was determined by the mean value of wells containing only 
buffer A, the RUC-NS3 fusion protein and A/G beads plus three standard deviations and is illustrated as dashed line. In the lower panels, liver specific 
parameters (GLDH, GGT and AST) are shown for each foal at the three follow-up time points as unfilled symbols, with the following reference ranges 
set by the laboratory: GLDH < 6 U/L, GGT < 20 U/L and AST < 170 U/L. (A) Foal # 9, (B) foal # 10, (C) foal # 17 and (D) foal # 19.
Table 1 Raw values of NPHV RNA and anti-NPHV NS3 anti-
bodies of the acutely infected foals
All collected follow-up serum samples were analyzed for the presence of NPHV 
RNA and anti-NPHV NS3 antibodies (ab) by qRT-PCR and LIPS, respectively. NPHV 
RNA titers are displayed as RNA copies/mL. Anti-NPHV NS3 ab values are given 









 Age in months 8 10 13.5
 Anti-NPHV NS3 ab (RLU) 6.57E + 04 2.06E + 05 2.18E + 05
 NPHV RNA (copies/mL) 8.67E + 06 4.45E + 06 9.27E + 06
Foal # 10
 Age in months 7.5 9.5 13
 Anti-NPHV NS3 ab (RLU) 8.19E + 03 3.50E + 04 4.86E + 04
 NPHV RNA (copies/mL) 2.15E + 07 6.88E + 06 5.81E + 07
Foal # 17
 Age in months 7 9.5 13
 Anti- PHV NS3 ab (RLU) 4.07E + 03 1.17E + 04 2.43E + 04
 NPHV RNA (copies/mL) 5.44E + 07 1.20E + 07 4.36E + 07
Foal # 19
 Age in months 6.5 8.5 12
 Anti-NPHV NS3 ab (RLU) 2.12E + 04 6.45E + 04 8.68E + 04
 NPHV RNA (copies/mL) 3.25E + 07 3.17E + 06 6.44E + 07
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In a retrospective study Matsuu et  al. also detected 
NPHV infections in 5 out of 7 young horses aged 
between 4 and 6 months and 2 years [16], supporting the 
time of infection in our foals. In three foals (foal # 9, # 
10, and # 19) maternal anti-NPHV NS3 antibodies were 
detected after birth until three to 6 months postpartum 
(Figures  1A, B and D). One could speculate that after 
degradation of maternal antibodies, the foals are more 
susceptible to a NPHV infection. However, foal # 17 
did not receive protection by maternal antibodies, yet it 
became infected at the same age as the three other foals. 
Moreover, it is not clear whether the maternal antibod-
ies protect against a NPHV infection. So far, the course 
of infection for NPHV in young horses has only been 
described by Ramsay et  al. who experimentally infected 
two foals at the age of 2–4  weeks and monitored them 
for more than 1  year post-infection [12]. These foals 
became viremic shortly after inoculation and remained 
persistently infected for the entire monitored 63  weeks. 
Anti-NPHV antibodies were detected from the age of 
approximately 8  weeks onwards and peaked 23  weeks 
post-infection. In the following weeks, the detection of 
antibodies decreased in parallel with the viral loads that 
sharply declined from 40 weeks post-infection onwards. 
Interestingly, in our study four naturally infected foals 
also remained persistently infected during the entire 
monitored time with high viral loads and were not able 
to clear the infection despite the presence of antibodies 
from the age of 7 to 9 months onwards. The reason for 
the inability of the four young horses to eliminate NPHV 
remains unclear. The development of the immune sys-
tem of young horses is only partially understood. It is 
known, that the onset of the adaptive immune response 
is delayed and antibody responses of type IgG4, IgG7 and 
IgE as well as T cell and cytokine responses slowly evolve 
within the first year of life [17]. However, to under-
stand the complex interaction of NPHV and the equine 
immune system, further research is required. It has been 
shown, that adult horses are often able to clear NPHV 
infection within 2 months after acute infection although 
persistently infected horses have also been described 
analogous to chronic HCV infection in humans [11, 12].
In conclusion, in four young horses the NPHV field 
infection progressed from acute to chronic infection. The 
four horses were not able to clear NPHV until the ages 
of 12–13  months despite the presence of antibodies for 
several months.
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